Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Khemaies S"'
Autor:
Zhi-Ming Shao, Li Cai, Shusen Wang, Xichun Hu, Kunwei Shen, Haibo Wang, Huiping Li, Jifeng Feng, Qiang Liu, Jing Cheng, Xinhong Wu, Xiaojia Wang, Hongyuan Li, Ting Luo, Jinping Liu, Khalid Amin, Khemaies Slimane, Yongping Qiao, Yongmin Liu, Zhongsheng Tong
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-12 (2024)
Abstract Background The global BOLERO-2 trial established the efficacy and safety of combination everolimus (EVE) and exemestane (EXE) in the treatment of estrogen receptor positive (ER +), HER2-, advanced breast cancer (ABC). BOLERO-5 investigated t
Externí odkaz:
https://doaj.org/article/54f05c5481a746a1854d62942484ed79
Autor:
Erman Mustafa, Biswas Bivas, Danchaivijitr Pongwut, Chen Lingwu, Yoke Fui Wong, Tarek Hashem, Chun Sen Lim, Bulent Karabulut, Hsiao-Jen Chung, Chandra Chikatapu, Sara Ingles, Khemaies Slimane, Ravindran Kanesvaran
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background Clinical effectiveness and safety data of pazopanib in patients with advanced or mRCC in real-world setting from Asia Pacific, North Africa, and Middle East countries are lacking. Methods PARACHUTE is a phase IV, prospective, non-
Externí odkaz:
https://doaj.org/article/15fd4b63d38742ba964f1220eda09e72
Autor:
Mustafa Erman, Bivas Biswas, Pongwut Danchaivijitr, Lingwu Chen, Yoke Fui Wong, Tarek Hashem, Chun Sen Lim, Bulent Karabulut, Hsiao-Jen Chung, Chandrasekhar Chikatapu, Sara Ingles, Khemaies Slimane, Ravindran Kanesvaran
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-2 (2021)
Externí odkaz:
https://doaj.org/article/c4088abcfc2b4a2295bba6b69afcf827
Autor:
Jacques Cadranel, Alexis B. Cortot, Hervé Lena, Bertrand Mennecier, Pascal Do, Eric Dansin, Julien Mazieres, Christos Chouaid, Maurice Perol, Fabrice Barlesi, Gilles Robinet, Sylvie Friard, Luc Thiberville, Clarisse Audigier-Valette, Alain Vergnenegre, Virginie Westeel, Khemaies Slimane, Alexandru Buturuga, Denis Moro-Sibilot, Benjamin Besse
Publikováno v:
ERJ Open Research, Vol 4, Iss 1 (2018)
Here we report our experience of ceritinib in crizotinib-pretreated patients with anaplastic lymphoma kinase (ALK) positive (ALK+) non-small cell lung cancer (NSCLC) in a French temporary authorisation for use (TAU) study. The French TAU study includ
Externí odkaz:
https://doaj.org/article/202e9719c04a4ff99eb02f9055c1241b
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.